CD6 and cancer: Since blocking CD6-CD318 interaction by itolizumab triggers cytotoxic responses of effector cells, it is plausible that the expression of CD318 in cancer cells induces inhibitory signals over the immune cells, acting as a tumor immunosuppressive mechanism.